CONNECT WITH US
HealthTech

HealthTech

#CTAD26: Priavoid’s amyloid-detangling pill PRI-002 fails Phase 2 study in Alzheimer’s

Endpoints News logo

Published on

Add as a preferred source on Google
#CTAD26: Priavoid’s amyloid-detangling pill PRI-002 fails Phase 2 study in Alzheimer’s

Pri­avoid’s amy­loid-de­tan­gling pill fails to mean­ing­ful­ly slow dis­ease in Phase 2 Alzheimer’s study

BOSTON — For near­ly a decade, the Ger­man biotech start­up Pri­avoid has been work­ing on a pill to break up small clumps of amy­loid pro­teins that …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.